U.S. Markets open in 3 hrs 17 mins

Anebulo Pharmaceuticals, Inc. (ANEB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.00+0.25 (+3.70%)
At close: 4:00PM EDT
7.00 0.00 (0.00%)
Pre-Market: 05:11AM EDT
Full screen
Loading interactive chart...
  • Benzinga

    The Danger of Synthetic Cannabinoids

    A problem of increasing social importance is the rise in the use of synthetic cannabis alternatives, commonly called K2 or Spice or a number of other brand names. In 2020, 2.4% of high school seniors tried synthetic cannabis. In contrast to marijuana where THC is the active molecule, these alternatives use a range of different, more potent compounds that activate the same pathways as THC, namely the CB1 cannabinoid receptor, which is responsible for the subjective effects of cannabinoid intoxica

  • The Dark Side of Cannabis Legalization and one Biotech Company's Solution
    Benzinga

    The Dark Side of Cannabis Legalization and one Biotech Company's Solution

    Photo credits: Tim Foster As of July 2021, 18 states have legalized recreational marijuana while another 18 have legalized cannabis solely for medical purposes. Meanwhile, Florida, Connecticut and Hawaii all have introduced legislation supporting legalization. As cannabis becomes decriminalized across the country, one of the unintended consequences is an increase in use — and inevitably, an increase in cannabis intoxication. Cannabis-associated emergency department visits have gone up by a compo

  • Business Wire

    Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

    AUSTIN, Texas, Jun 21, 2021--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ("Anebulo" or the "Company"), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid intoxication and substance addiction, today reported recent business highlights and announced financial results for the fiscal year 2021 third quarter, ended March 31, 2021.